[New medications for patients with type 2 diabetes]

Soins. 2014 Oct:(789):15-8.
[Article in French]

Abstract

Type 2 diabetes is characterised by insulin resistance and deficiencywhich explains the multitude of molecules developed for its treatment.The beneficial effects of metformin and sulfamides have been demonstrated. Over the last 10 years, new molecules have appeared: acarbose, repaglinide and incretins.

Publication types

  • English Abstract

MeSH terms

  • Carbamates / therapeutic use
  • Diabetes Mellitus, Type 2 / drug therapy*
  • Dipeptidyl-Peptidase IV Inhibitors / therapeutic use
  • Drug Therapy, Combination
  • Glucagon-Like Peptide 1 / agonists
  • Glycoside Hydrolase Inhibitors / therapeutic use
  • Humans
  • Hypoglycemic Agents / therapeutic use*
  • Incretins / therapeutic use
  • Piperidines / therapeutic use

Substances

  • Carbamates
  • Dipeptidyl-Peptidase IV Inhibitors
  • Glycoside Hydrolase Inhibitors
  • Hypoglycemic Agents
  • Incretins
  • Piperidines
  • repaglinide
  • Glucagon-Like Peptide 1